Sign In
Step 1
Unite with Fellow Investors
Step 2
Choose the Best Attorney
Step 3
Provide Documents
Step 4
Follow Case Progress
Step 5
Get Payout
SLRN.US

Acelyrin (SLRN) Clinical Trial Case

C.D. California
Court
2:23-cv-09672
Case number
04 May 2023
Class period Start
11 Sept 2023
Class period End
  • Acelyrin allegedly exaggerated one of its main product effectiveness.
  • On September 13, 2023, the truth came out, leading to a 16% $SLRN fall.
Acelyrin went public in May, 2023, selling 30 million shares at $18.00 each.

In September, Acelyrin revealed disappointing results for izokibep (one of its main drugs) in a clinical trial.

This news caused $SLRN fall by 16% and $203M loss of market cap, damaging shareholders.

Given all this information, investors have reason to suspect that Acelyrin misled about izokibep's success, leading to an overestimation of its business prospects after going public.
Alleged Offence
Mismanagement
Misleading Statements
Omissions
Suspected Party
Directors
Management
Security Type
Stocks
Trade Direction
Long
Shock Event Date
13 September 2023
Filing date
15 November 2023
Lead Plaintiff Deadline
15 January 2024
Judge
Maria A Audero
Collecting participants…
Created by Polina Foster, Scout

ACELYRIN, Inc

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candi...

    Ticker
    SLRN.US
    ISIN
    US00445A1007
    CIK
    1962918
    Sector
    Healthcare
    Industry
    Biotechnology
    Country
    USA
    Address
    4149 Liberty Canyon Road, Agoura Hills, CA, United States, 91301